Branch Retinal Vein Occlusion Clinical Trial
Official title:
Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects
Assessment of retinal vessel calibers combined with bidirectional Fourier domain optical coherence tomography (FDOCT) for measurement of retinal blood velocities is a new and sophisticated method for assessing retinal blood flow in humans. The valid measurement of retinal blood flow is of significant importance, because it is known that major ophthalmic diseases are associated with alterations in blood flow. As such, retinal vascular occlusive diseases represent a major cause of visual impairment and blindness. The prevalence of the disease is between 0.7 and 1.6%. Compression of the retinal veins at arterio-venous (AV) crossings plays an important role in the development of branch retinal vein occlusion (BRVO). The mechanical narrowing of the vessel lumen is supposed to be the mechanism behind this fact. The present study should elucidate how BRVO influences retinal blood flow at retinal vessel crossings in comparison to healthy control subjects. Retinal blood flow at retinal bifurcations will also be assessed. In addition, a fundus image will be taken to assess retinal oxygen saturation. For the first time we use a combination of a dynamic vessel analyzer (DVA) with bidirectional Fourier domain optical coherence tomography (FDOCT) to assess retinal blood flow. Whereas the DVA provides information concerning retinal vessel caliber, FDOCT provides laser Doppler information in addition to conventional optical coherence tomography, allowing the observation of blood flow dynamics simultaneously. In the present study we hypothesize that the DVA in combination with FDOCT is a suitable new tool for the assessment of blood flow in healthy subjects and in patients with BRVO.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 2, 2023 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Inclusion criteria for healthy subjects - Men and women aged over 18 yrs - Nonsmokers - Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant - Normal ophthalmic findings, ametropia < 6 Dpt. Inclusion criteria for patients with BRVO - Age = 18a - Patients with branch retinal vein occlusion with a history of 3 to 9 months in one eye - No history of BRVO in the fellow eye - Temporal inferior or superior vein occlusion - Ametropia < 6 Dpt Exclusion Criteria: Any of the following will exclude a healthy subject from the study: - Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study (except oral contraceptive) - Symptoms of a clinically relevant illness in the 3 weeks before the first study day - Blood donation during the previous 3 weeks - Pregnancy - Any abnormalities preventing reliable measurements as judged by the investigator Any of the following will exclude a patient with BRVO from the study: - Presence of intraocular pathology other than branch retinal vein occlusion - Blood donation during the previous 3 weeks - Clinical trial in the 3 week preceding the study - Pregnancy - Any abnormalities preventing reliable measurements as judged by the investigator |
Country | Name | City | State |
---|---|---|---|
Austria | Department of Clinical Pharmacology, Medical University of Vienna | Vienna |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Retinal blood flow | once on the study day | ||
Secondary | Retinal vessel diameter | once on the study day | ||
Secondary | Retinal blood velocity | once on the study day | ||
Secondary | Retinal oxygen saturation | once on the study day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Active, not recruiting |
NCT04120311 -
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
|
Phase 1 | |
Not yet recruiting |
NCT04601688 -
Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
|
N/A | |
Completed |
NCT01968239 -
Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT
|
Phase 2 | |
Completed |
NCT00612261 -
Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion
|
N/A | |
Not yet recruiting |
NCT03637283 -
Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage
|
N/A | |
Completed |
NCT01976338 -
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
|
Phase 3 | |
Completed |
NCT01471691 -
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
|
Phase 1/Phase 2 | |
Completed |
NCT01247220 -
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
|
Phase 2 | |
Terminated |
NCT00642226 -
Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
|
Phase 3 | |
Terminated |
NCT05127525 -
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
|
Phase 3 | |
Completed |
NCT01599650 -
Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
|
Phase 3 | |
Active, not recruiting |
NCT04120636 -
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
|
Phase 1 | |
Recruiting |
NCT01975103 -
Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases
|
Phase 2 | |
Recruiting |
NCT01348633 -
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
|
N/A | |
Completed |
NCT04740905 -
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
|
Phase 3 | |
Recruiting |
NCT02527733 -
Retinal Sensitivity in BRVO After Anti-VEGF Therapy
|
Phase 4 | |
Completed |
NCT01396057 -
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
|
Phase 3 | |
Terminated |
NCT03802630 -
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
|
Phase 3 | |
Completed |
NCT02478515 -
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
|
Phase 4 |